Novo Nordisk's Wegovy oral tablet receives TGA approval in Australia
Australia's Therapeutic Goods Administration has approved the oral semaglutide pill Wegovy for weight management and cardiovascular risk reduction, with market entry expected later this year.
The Therapeutic Goods Administration approved Novo Nordisk's Wegovy (semaglutide) oral tablet on Tuesday, marking the first GLP-1 weight-loss pill cleared for use in Australia. The medication is authorised for eligible adults to aid weight management and to lower the risk of major adverse cardiovascular events.
Until now, Australian patients could only obtain GLP-1 therapies as weekly injections. The new formulation can be taken each morning on an empty stomach and remains stable at room temperature, unlike the injectable version that requires refrigeration. Approved strengths include 1.5 mg, 4 mg, 9 mg and 25 mg.
A Novo Nordisk spokesperson said the company is “working towards bringing this new treatment option to eligible Australians, with anticipated availability later this year,” and will provide confirmed timing when possible.
Dr Karen Spielman, chair of the RACGP’s Specific Interests Psychological Medicine group, said the approval could improve access and affordability for medical weight loss but cautioned that expanded prescribing must be accompanied by appropriate patient screening and support. She noted reports of hospitalisations among patients with eating disorders and a TGA warning linking GLP-1 drugs to suicidal thoughts, emphasizing the need for clear guidelines and increased Medicare rebates to allow thorough consultations.
The oral pill’s introduction follows a rapid rise in GLP-1 sales in Australia, which a University of New South Wales study reported increased nearly tenfold from 2020 to 2025. The TGA will still review packaging and production processes before the product reaches pharmacies.